Internal Medicine/Primary care Updates and CME

Internal Medicine/Primary care Updates and CME is organized by Brilliant Board Prep LLC.

Available: October 01, 2025 – October 01, 2027

Topics Covered:
New and Notable Drugs - Recent Additions to Clinical Practice

• Suzetrigine – Novel NaV1.8 sodium-channel blocker offering a non-opioid option for acute pain management
• Methotrexate in Osteoarthritis – Expanding indications for disease-modifying therapy in degenerative joint disease
• Mavacamten – Cardiac myosin inhibitor improving management of obstructive hypertrophic cardiomyopathy
• Finerenone – Non-steroidal mineralocorticoid receptor antagonist with proven renal and cardiovascular benefit in diabetic CKD
• Vonoprazan – Potassium-competitive acid blocker (P-CAB) as an emerging alternative to PPIs for GERD
• Sotatercept – Activin-signaling modulator for pulmonary arterial hypertension
• Aripiprazole – Reviewed in the context of hormone therapy and chronic pain syndromes

New Treatments and Emerging Clinical Concepts:

• PREVENT Risk Calculator – Updated AHA/ACC algorithm for precise cardiovascular risk stratification
• HCTZ vs Chlorthalidone – Comparative data guiding optimal thiazide selection
• Transcatheter Mitral Valve Repair – Expanding interventional options for mitral regurgitation
• Lifestyle Medicine – Mediterranean Diet – Evidence synthesis for cardiometabolic risk reduction
• Health Equity & Social Determinants of Health – Integrating population-level data into individualized care
• Aspirin for Primary Prevention – Reevaluated thresholds based on 2023–2024 guideline revisions
• Antimicrobial Stewardship & Resistance – Updated stewardship frameworks and resistance trends
• Direct Oral Anticoagulants (DOACs) – Evolving data on indications, dosing, and reversal strategies
• Chronotherapy in Hypertension – Timing of dosing and outcome impact
• Albumin in Sepsis & AKI – Current evidence for fluid selection
• Remote Hypertension Management – Implementation of telemonitoring models
• Subclinical Hypothyroidism & Fracture Risk – Thyroid–bone interaction studies
• Endocrine Tumors & Emergencies – Recognition and acute management
• Critical Illness Myopathy – Prevention and recovery in ICU weakness
• Status Epilepticus & Non-Convulsive Seizures – Diagnostic and therapeutic updates

Educational Objectives:
Upon completion of this activity, participants should be able to:

• Integrate 2024 ADA and AHA recommendations into diabetes and cardiovascular care
• Describe the appropriate clinical use of novel agents such as SGLT2i, GLP-1 RAs, and ARNIs
• Select suitable candidates for newly approved medications using evidence-based criteria
• Modify existing treatment plans considering comorbidities and drug interactions
• Interpret revised thresholds and diagnostic tools for CKD, iron deficiency, and heart failure
• Utilize updated scoring systems and imaging techniques for diagnosis and therapy

Key Features:
Ultimate Convenience & Accessibility

• Mobile App Access – Study during commutes, between patients, or at home
• Learn Anywhere, Anytime – Hospital cafeteria, call room, or your couch
• Pause & Resume – Pick up exactly where you left off on any device